--- title: "Pre-market hot trades in US stocks: Star Fashion Culture pre-market down 12.90%; Signing Day Sports pre-market down 12.72%" type: "News" locale: "en" url: "https://longbridge.com/en/news/276709273.md" description: "Star Fashion Culture pre-market down 12.90%; Signing Day Sports pre-market down 12.72%; Vir Biotechnology pre-market up 52.22%; Silo Pharma pre-market up 40.68%; Blue Hat pre-market up 26.90%" datetime: "2026-02-24T09:12:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276709273.md) - [en](https://longbridge.com/en/news/276709273.md) - [zh-HK](https://longbridge.com/zh-HK/news/276709273.md) --- # Pre-market hot trades in US stocks: Star Fashion Culture pre-market down 12.90%; Signing Day Sports pre-market down 12.72% **Popular Pre-Market Trades in U.S. Stocks** Star Fashion Culture, down 12.90% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Signing Day Sports is down 12.72% in pre-market trading. Based on recent key news: 1. On February 21, Signing Day Sports announced the terms of its business merger with BlockchAIn, where shareholders will exchange shares based on a price-related ratio. This news has increased market uncertainty about the company's future, leading to a pre-market drop of 12.72%. Source: SEC announcement. 2. On February 21, technical sentiment signals indicated a sell, weakening market confidence in Signing Day Sports, further exacerbating the stock price decline. Source: TipRanks. 3. On February 20, SEC filings disclosed merger details, raising market concerns about the adjustment of shareholder equity ratios post-merger, impacting the stock price. Source: Public Technologies. The sports technology industry faces integration challenges, with significant capital outflows. **Top Gainers in U.S. Stocks Pre-Market** Vir Biotechnology is up 52.22% in pre-market trading. Based on recent key news: 1. On February 24, Vir Biotechnology reached a collaboration agreement with Astellas Pharma to develop and commercialize VIR-5500 for the treatment of prostate cancer. This agreement includes a $335 million upfront payment and recent milestone payments, with Vir eligible for up to $1.37 billion in development, regulatory, and sales milestone payments, as well as double-digit royalties on sales outside the U.S. This news drove the stock price up about 55%. 2. On February 24, Vir Biotechnology reported fourth-quarter sales that exceeded expectations, with revenue reaching $64.07 million, a year-over-year increase of 417.9%. This performance boosted market confidence in the company's future growth, leading to a significant stock price increase. 3. On February 23, Vir Biotechnology released positive Phase I trial results for VIR-5500, showing dose-dependent anti-tumor activity, with 82% PSA50 and 53% PSA90 declines, and a RECIST-evaluable objective response rate of 45%. This result further supported the stock price increase. The biotechnology industry faces regulatory risks, with high stock price volatility. Silo Pharma is up 40.68% in pre-market trading. Based on recent key news: 1. On February 23, Silo Pharma announced a $1 million stock repurchase plan. This move is seen as the company's management believing that current market conditions undervalue its stock and aims to enhance shareholder value. Following this announcement, the stock price significantly increased Source: Reuters On February 23, Silo Pharma released relevant information through the EDGAR system, further confirming the details of its repurchase plan. The disclosure of this information has increased market confidence in the company's stock. Source: EDGAR On February 23, Silo Pharma's technical sentiment signal indicated a strong sell, but the announcement of the repurchase plan changed market sentiment, driving the stock price up. Source: Public Technologies The biopharmaceutical industry has been highly volatile recently and requires attention. Blue Hat rose 26.90% in pre-market trading. Based on recent key news: On February 21, Blue Hat announced its shift from augmented reality gaming to global merchandise trading, planning to raise funds through stock issuance. This move aims to provide the company with more operating capital and general corporate purposes. Although this news caused the stock price to plummet by 75.17% on February 21, market expectations for its transformation plan drove the stock price up by 26.90% in pre-market trading. Source: Benzinga On February 23, Blue Hat is expected to complete the stock issuance, further supporting its business transformation. This news has enhanced investor confidence in the company's future development, driving the stock price up. Source: Benzinga No other significant news recently. The transformation in the merchandise trading industry is attracting attention ### Related Stocks - [STFS.US](https://longbridge.com/en/quote/STFS.US.md) - [SGN.US](https://longbridge.com/en/quote/SGN.US.md) ## Related News & Research - [Star Media Group Berhad (KLSE:STAR) Is About To Go Ex-Dividend, And It Pays A 4.5% Yield](https://longbridge.com/en/news/286657568.md) - [TGT Stock Alert: What to Know as Target Taps Former Walmart Exec](https://longbridge.com/en/news/286957668.md) - [Should you invest $1,000 in AGNC Investment right now?](https://longbridge.com/en/news/286802595.md) - [Nike Turns to Google's AI to Lift Sales, But NKE Stock Keeps Falling](https://longbridge.com/en/news/286956210.md) - [AI is not replacing workers on a large scale so far, says Bank of Canada](https://longbridge.com/en/news/286540351.md)